Evaluation of Concordance Between Exhaled Air Test (eBAM-CoV) and RT-PCR to Detect SARS-CoV-2
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorCentre Hospitalier Universitaire de Nīmes
About this trial
During the COVID-19 pandemic, testing primarily relied on the use of nasopharyngeal swabs to detect the SARS-CoV-2 virus, responsible for the disease. However, this technique has several limitations, including the variable quality of swabs, its invasive nature, and arbitrariness in the choice of the number of cycles. Furthermore, it does not allow for the detection of viral proteins.
To overcome these limitations, researchers developed the eBAM-CoV test, patented for the detection of viral proteins in the exhaled air of COVID-19 patients. This portable device provides an immediate assessment of the "viral load" with both quantitative and qualitative results, showing promise for early virus detection.
The researchers hypothesize that the eBAM-CoV test is likely to exhibit a satisfactory concordance with the reference RT-PCR test in the detection of COVID-19, especially among symptomatic patients or closed contacts.
Eligibility criteria
Qualifiers
Adult male or female patients over 18 years of age (≥)
Suspected of being infected with COVID-19 (symptomatic or contact case) and consulting for RT-PCR screening.
Disqualifiers
Inability to understand the procedures to use the device
Patient participating in an another interventional study
Patient in exclusion period determined by another study
Patient under court protection or guardianship
Trial design
Treatments tested in this trial
- eBAM Cov Testing
Treatment groups
250 Participants
are divided into 1 treatment groupSponsors and collaborators
Centre Hospitalier Universitaire de Nīmes
Lead sponsor
University of Nimes
Collaborator
brains' laboratory sas, FRANCE
Collaborator
Source ClinicalTrials.gov